Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies.
Kakuda TN, Berckmans C, De Smedt G, Leemans R, Leopold L, Peeters M, Nijs S, Vyncke V, van Solingen-Ristea R, Hoetelmans RM. Kakuda TN, et al. Among authors: nijs s. Int J Clin Pharmacol Ther. 2013 Sep;51(9):725-37. doi: 10.5414/CP201770. Int J Clin Pharmacol Ther. 2013. PMID: 23924679 Clinical Trial.
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Kakuda TN, Wade JR, Snoeck E, Vis P, Schöller-Gyüre M, Peeters MP, Corbett C, Nijs S, Vingerhoets J, Leopold L, De Smedt G, Woodfall BJ, Hoetelmans RM. Kakuda TN, et al. Among authors: nijs s. Clin Pharmacol Ther. 2010 Nov;88(5):695-703. doi: 10.1038/clpt.2010.181. Epub 2010 Sep 29. Clin Pharmacol Ther. 2010. PMID: 20881958 Clinical Trial.
Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
Tudor-Williams G, Cahn P, Chokephaibulkit K, Fourie J, Karatzios C, Dincq S, Opsomer M, Kakuda TN, Nijs S, Tambuyzer L, Tomaka FL; PIANO study group. Tudor-Williams G, et al. Among authors: nijs s. HIV Med. 2014 Oct;15(9):513-24. doi: 10.1111/hiv.12141. Epub 2014 Mar 3. HIV Med. 2014. PMID: 24589294 Free article. Clinical Trial.
Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients.
Orrell C, Felizarta F, Nell A, Kakuda TN, Lavreys L, Nijs S, Tambuyzer L, Van Solingen-Ristea R, Tomaka FL. Orrell C, et al. Among authors: nijs s. AIDS Res Treat. 2015;2015:938628. doi: 10.1155/2015/938628. Epub 2015 Jan 15. AIDS Res Treat. 2015. PMID: 25664185 Free PMC article.
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
Towner W, Lalezari J, Sension MG, Wohlfeiler M, Gathe J, Appelbaum JS, Bellman P, Gottlieb MS, Ryan R, Nijs S, Hoogstoel A, Van Solingen-Ristea R, Witek J. Towner W, et al. Among authors: nijs s. J Acquir Immune Defic Syndr. 2010 Apr;53(5):614-8. doi: 10.1097/QAI.0b013e3181cdebb1. J Acquir Immune Defic Syndr. 2010. PMID: 20134329 Clinical Trial.
197 results